What Are Exosomes?
Exosomes are tiny extracellular vesicles, typically between 50 and 200 nanometres in diameter, that are naturally produced by cells throughout the body. To put that size in perspective, a single exosome is roughly 1,000 times smaller than the width of a human hair.
Their biological role is communication. Exosomes act as intercellular messengers, transporting proteins, lipids, messenger RNA (mRNA) and microRNA (miRNA) between cells. This molecular cargo carries instructions that regulate a wide range of biological processes, from immune responses and inflammation to tissue repair and cell growth.
In the context of hair loss, the relevant function is this: exosomes can deliver regenerative signals directly to the cells responsible for hair growth, specifically the dermal papilla cells at the base of each hair follicle and the stem cells within the follicle itself. These signals can help reactivate biological processes that have slowed down or stopped, which is exactly what happens when follicles miniaturise and hair begins to thin.
How Exosome Therapy Works for Hair Loss
Most forms of hair loss, whether androgenetic alopecia (pattern hair loss) or telogen effluvium (stress or illness-related shedding), involve a common set of biological problems: follicle miniaturisation, disrupted signalling between cells, chronic low-grade scalp inflammation, and a progressively shorter growth (anagen) phase. Over time, affected follicles spend more time resting and less time growing, producing thinner, weaker hairs until visible thinning becomes apparent.
Exosome therapy aims to intervene in this process by delivering a concentrated payload of regenerative signals directly to the scalp. The treatment typically involves applying or microneedling an exosome solution into the affected areas, where the vesicles can interact with the follicle cells and their surrounding environment.
The proposed mechanisms of action include:
Follicle reactivation. The growth factors and signalling proteins carried by exosomes interact with dermal papilla cells, encouraging dormant follicles to re-enter the active growth (anagen) phase. Preclinical studies have demonstrated that mesenchymal stem cell-derived exosomes can stimulate dermal papilla cell proliferation and activate the Wnt/beta-catenin signalling pathway, which plays a central role in the hair growth cycle. (Source: Stem Cell Reviews and Reports, 2024 systematic review)
Anti-inflammatory action. Chronic perifollicular inflammation is a contributing factor in many types of hair loss. The miRNA cargo within exosomes includes molecules with targeted anti-inflammatory properties, which help create a scalp environment where follicles can function and cycle more effectively.
Improved blood supply. Exosomes promote neovascularisation (the formation of new blood vessels) around the follicle. Better blood supply means improved delivery of oxygen and nutrients to the dermal papilla, supporting the metabolic demands of actively growing hair.
Extended growth phase. By improving the signalling environment around the follicle, exosome therapy may help extend the anagen phase and shorten the telogen (resting) phase, resulting in longer, thicker hair growth before the follicle cycles back to rest.
What Does the Clinical Evidence Say?
It is important to be straightforward about where the science currently stands. Exosome therapy for hair loss is a rapidly developing field, but it is still in its early stages compared to treatments like minoxidil or finasteride, which have decades of large-scale clinical trial data behind them.
That said, the evidence published so far is promising.
A 2025 systematic review published in Dermatology and Therapy (Queen and Avram) examined the available clinical literature on exosome treatments for hair loss. Across the studies reviewed, 125 patients had received exosome treatment, with the majority showing measurable improvements in hair density. Side effects were rare. However, the authors emphasised the need for larger, well-designed clinical trials with extended follow-up periods before firm conclusions about long-term efficacy and safety can be drawn. (Source: PubMed)
A 2025 systematic review in Clinical, Cosmetic and Investigational Dermatology (Al Ameer et al.) analysed 11 clinical studies, including two randomised controlled trials, three retrospective studies and three prospective single-arm studies. The review found that exosome-based interventions demonstrated positive effects on hair regrowth across multiple study designs and exosome sources, though the authors noted significant heterogeneity between studies and called for standardised manufacturing and larger trials. (Source: Dove Medical Press / PubMed)
A separate 2024 prospective study (Ersan et al.) examined the outcomes of mesenchymal stem cell-derived exosome injections in 30 male patients with androgenetic alopecia. The results showed a statistically significant increase in hair density at both 4 and 12 weeks post-treatment, with no reported adverse effects. (Source: Aesthetic Plastic Surgery)
In terms of product-specific evidence, Dr. Inigo de Felipe, a dermatologist with practices in Barcelona and London, completed a two-year clinical study using ASCE+ HRLV (the exosome product used at House of Aesthetics). He reported that it produced improvements that were greater than those achieved with oral dutasteride, topical minoxidil or PRP alone, with particularly notable results in the frontal area of the scalp, an area where many hair loss treatments struggle. (Source: ExoCoBio / PR Newswire)
A balanced perspective
While these results are encouraging, a few caveats are worth noting. Most published studies have small sample sizes. Long-term data beyond 12 months is limited. There is no universally standardised exosome product or protocol, which means results can vary between clinics depending on the product used and the delivery method. And exosome therapy does not address the underlying cause of hair loss (such as hormonal factors in androgenetic alopecia), which means ongoing maintenance is typically needed to sustain results.
None of this makes exosome therapy ineffective; it simply means the evidence base is still maturing. For patients who want to make an informed decision, understanding both the promise and the current limitations is essential.
Skip to content
